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The recreational use of cannabis can have persistent adverse effects on mental health.
Delta-9-tetrahydrocannabinol (THC) is the main psychoactive constituent of cannabis, and
most, if not all, of the effects associated with the use of cannabis are caused byTHC. Recent
studies have suggested a possible protective effect of another cannabinoid, cannabid-
iol (CBD). A literature search was performed in the bibliographic databases PubMed,
PsycINFO, and Web of Science using the keyword “cannabidiol.” After removing duplicate
entries, 1295 unique titles remained. Based on the titles and abstracts, an initial selection
was made.The reference lists of the publications identified in this manner were examined
for additional references. Cannabis is not a safe drug. Depending on how often someone
uses, the age of onset, the potency of the cannabis that is used and someone’s indi-
vidual sensitivity, the recreational use of cannabis may cause permanent psychological
disorders. Most recreational users will never be faced with such persistent mental illness,
but in some individuals cannabis use leads to undesirable effects: cognitive impairment,
anxiety, paranoia, and increased risks of developing chronic psychosis or drug addiction.
Studies examining the protective effects of CBD have shown that CBD can counteract
the negative effects of THC. However, the question remains of how the laboratory results
translate to the types of cannabis that are encountered by real-world recreational users.
Keywords: tetrahydrocannabinol, cannabidiol, cannabis, psychosis, anxiety, drug dependence, cognition
Tetrahydrocannabinol (THC) is the main psychoactive substance
in cannabis. Cannabidiol (CBD) is a cannabinoid that appears in
cannabis resin but rarely in herbal cannabis. In recent years, many
positive attributes have been ascribed to CBD. Is cannabis that con-
tains CBD less harmful than cannabis without CBD? Are people
who smoke cannabis resin, therefore, less susceptible to psychosis
or less likely to become addicted than are people who smoke herbal
marijuana? In this article, several of the health aspects of CBD will
be reviewed. The article will focus on the role played by CBD
in contributing to the psychological effects that are experienced
during recreational cannabis use.
PHARMACOLOGY
Cannabis sativa contains more than 80 different cannabinoids,
of which THC is principally responsible for the pharmacological
actions, including the psychoactive effects. THC binds to specific
proteins in the brain – the cannabinoid receptors (CB-Rs) (1). Two
different receptors have been discovered: the CB1 and CB2 recep-
tors (2, 3). CB1-R is mainly found in the central nervous system
(CNS); CB2-R is predominantly present in the immune system
(3–5). Endocannabinoids are naturally occurring substances that
attach to these receptors (6–8).
Cannabinoid receptors, endocannabinoids, and the enzymes
involved in the synthesis and degradation of these substances
together form the endocannabinoid system (9). The activation
of the CB-Rs affects the actions of various neurotransmitters,
such as acetylcholine, dopamine, GABA, glutamate, serotonin,
norepinephrine, and endogenous opioids (10, 11). Under nor-
mal physiological circumstances, CB-Rs are activated by endo-
cannabinoids (12). The activation of CB-Rs by endocannabinoids
inhibits excessive neurotransmitter release. Endocannabinoids are
lipid-soluble compounds, which prevent them from traveling long
distances within the brain. As a consequence of this feature, endo-
cannabinoids are ideally suited for small-scale, local physiological
processes (13).
Tetrahydrocannabinol mimics the effect of endocannabinoids.
In contrast to these substances, THC is not rapidly broken down
at the site of operation, and it not only works at specific loca-
tions but simultaneously activates all CB receptors throughout the
brain (14).
The mechanisms by which CBD exerts its effect are not pre-
cisely known, but it is clear that the pharmacological actions of
CBD follow from many different mechanisms [for reviews, see
Ref. (15, 16)]. CBD weakly binds to CB-Rs but is capable of antag-
onizing the effects of THC, even when the former is present in low
doses. By inhibiting the degradation of the endogenous cannabi-
noid anandamide, CBD intensifies, and prolongs its effect (17).
The (extended) presence of anandamide prevents THC from inter-
acting with CB-Rs. CBD also interacts with several other recently
discovered CB-Rs, and it is an agonist for the 5-HT1A receptor (18,
19), which may explain some of the antipsychotic and anxiolytic
effects of CBD (20). Through its effect on intracellular calcium
concentrations, CBD might protect neurons against the possible
neurotoxic effects of THC (21). CBD itself has almost no effect
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on normal physiological processes. Only when a stimulus (such as
pain or a shock reaction) or another cannabinoid (such as THC)
upsets the normal “tone” of the endocannabinoid system is the
effect of CBD expressed (12).
The amount of CBD administered, the ratio of CBD to THC
and the timing of administration all seem to be important in deter-
mining the possible effects of CBD (22, 23). Most clinical studies
on the effects of CBD are not relevant for generalizing to the effects
of CBD in “recreational” cannabis users. In many of these stud-
ies, the doses that have been used are not relevant to the situation
typically encountered by recreational cannabis users.
Clinical research has focused on the physical effects of cannabis
use, such as pain relief, appetite promotion, and inflammation. For
recreational cannabis users, the substance’s psychological effects
are the most important. In many experimental studies, the routes
of administration used for both THC and CBD are not compara-
ble to the routes of administration found in recreational cannabis
use. The high dosages of CBD that have been used in experimental
studies increase the concentration of CBD in the blood to levels
that can never be reached by smoking a joint. The method that is
most comparable to smoking is exposure through a vaporizer, but
little research has been conducted involving the administration
of cannabis, THC, or CBD via a vaporizer (24, 25). Therefore, it
is unknown to what extent the effects of a single administration
procedure can be extrapolated to recreational cannabis users given
such differences in usage patterns.
TOXICOLOGY OF CBD
Research on the pharmacological and toxicological properties of
CBD has been performed on different types of animals. In general,
the metabolism of CBD in different species seems similar to that
observed in humans, but some differences exist (26). It is possi-
ble that differences in metabolism and kinetics among different
species have been responsible for some of the observed differences
in pharmacological and toxicological effects.
Little research has focused on the safety and side effects of CBD
in humans. However, several studies have described the effects of
CBD for therapeutic applications in clinical trials. Only a few, gen-
erally mild side effects have been observed after administration of
CBD in these human studies, though a wide range of effects over
a wide dose range, including acute and chronic administration,
have been examined. Few undesirable effects are reported, and
tolerance for CBD does not seem to occur.
Based on an extensive literature review, Bergamaschi and col-
leagues concluded that CBD, to the extent that it has been stud-
ied, is a substance with low toxicity (27). Notably, however, the
absence of harmful effects of CBD in humans has been described
in research that was not primarily aimed at investigating these
same side effects or toxicities of CBD. Because no specific research
on these issues has been performed, it is currently impossible to
draw conclusions about differences in toxicity between hashish
and marijuana.
Chronic cannabis use is associated with psychiatric toxicity
and cannabis has been implicated in the etiology of long-term
psychiatric conditions (28). Several in vivo brain scanning tech-
niques have been conducted to investigate whether chronic, heavy
cannabis use leads to structural changes in the brain [for reviews,
see Ref. (29, 30)]. The results of these studies have been rela-
tively inconsistent. In general, no differences in total brain volume
between cannabis users and non-users have been found. With
respect to CB1 receptor concentrations in different parts of the
brain, it can be expected that structural changes after chronic
intensive cannabis use would most likely eventually be situated
in the orbitofrontal cortex (OCC), the anterior cingulate cortex
(ACC), the striatum, the amygdala, and the hippocampus (31–33).
In some structural magnetic resonance imaging (sMRI) studies,
reductions in the volumes of the hippocampus, the amygdala, and
the cerebellum have been found in adult heavy cannabis users
when compared with healthy controls (21, 34, 35). Using a PET
scan technique, Wilson and colleagues found age-dependent mor-
phological changes in early-onset cannabis users. In subjects who
started their cannabis use before the age of 17, it has been found
that the ratio of cortical gray to white matter is smaller when com-
pared with subjects who had started using cannabis after their 17th
birthdays (36). Structural abnormalities due to chronic cannabis
use have been most consistently identified in the hippocampus
(21, 34, 35). Using a voxel-based morphometry (VBM) approach,
Demirakca and colleagues studied gray matter (GM) concentra-
tions and volumes of the hippocampus in 11 chronic recreational
cannabis users and 13 healthy controls and correlated their find-
ings with THC and CBD measurements made from hair analyses.
They found that cannabis users showed lower GM volume in the
right anterior hippocampus. Higher THC and lower CBD were
associated with this hippocampal volume reduction, suggesting
neurotoxic effects of THC and neuroprotective effects of CBD.
The conflicting results among volumetric brain studies seem
to result from differences in time span (e.g., age of onset), pat-
terns of cannabis use (e.g., frequency, duration of use, cumulative
lifetime use), and type of cannabis used (e.g., potency, CBD/THC
ratio) (29, 30).
PSYCHOLOGICAL EFFECTS
The effects of cannabis on psychological functioning mainly con-
cern psychotic symptoms, anxiety, depression, cognitive function-
ing, and the potential for abuse and dependency. Several studies
show that high doses of cannabis can provoke acute and tran-
sient psychotic reactions in both “healthy” users and in people
with a certain predisposition for psychosis (37–39). These effects
are dose-related (i.e., more THC produces a greater effect) and
are stronger and longer-lasting in naive and occasional users than
they are in frequent and transient cannabis users. Rottanburg and
colleagues were the first to propose a protective effect of CBD on
THC-induced psychosis. They suggested that the high incidence of
cannabis-related psychosis among their patients occurred because
cannabis variants in South Africa are more potent in terms of THC
content and because they lack CBD (40).
As early as 1982, there were indications that the psychosis- and
anxiety-inducing effects of THC can be suppressed by CBD (41,
42). Several other studies have found support for the antipsychotic
effects of CBD. fMRI studies have shown that the effects of THC
are correlated with a decrease in brain activity in the striatum. The
striatum plays an important role in planning activities, modulat-
ing motor activity (movement), and performing cognitive tasks.
CBD has been found to increase the activity in this brain area (43).
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Moreover, in other brain areas, the effects of CBD on neurological
activity have been shown to be opposite those of THC.
In one Dutch and three English studies, associations between
the consumption of certain types of cannabis and the occurrence
of psychotic symptoms were reported (41–47). The results of these
“naturalistic” studies suggest that CBD exerts a dampening effect
on THC-induced psychotic symptoms. It is not clear for which
CBD/THC ratio and for what minimum CBD concentration the
protective effects of CBD may be expressed. The main features of
these “naturalistic” studies are summarized in Table 1.
Longitudinal studies that have investigated the relationship
between chronic cannabis use and the occurrence of psychosis
have shown that cannabis use increases the risk of later psychotic
symptoms and disorders by a factor of 2–3. The magnitude of the
risk depends on the degree of exposure, the age of onset of cannabis
use and the “vulnerability” of the user (50–52). No longitudinal
studies have distinguished between the type of cannabis having
been used, and no studies give an indication of the THC/CBD
ratio.
One case-control study has shown an association between the
occurrence of a first psychotic episode and the use of high-potency
cannabis (skunk or sinsemilla) (47). Patients with psychotic symp-
toms had more frequently used skunk or sinsemilla cannabis
instead of hashish than had non-patients. Patients experiencing
first-episode psychosis were also more likely to be daily users
of high-potency cannabis than were controls. This finding sug-
gests that both the daily use and consumption of cannabis with a
high-THC and low-CBD content increase the risk of developing
psychosis.
Cannabis use can lower the age of a first psychotic episode (53,
54). Epidemiological and clinical studies suggest an adverse effect
of cannabis use on the course of the disease in terms of relapse,
exacerbation of symptoms and number of hospitalizations (38,
55–57). With the exception of a study by Di Forti et al. (47),
no study has investigated the use of different types of cannabis
in patients with a psychotic disorder. The extent to which the
presence or absence of CBD in cannabis will influence the early
occurrence of a first-episode psychosis or to what extent it will
affect the course of the disease is, therefore, unknown.
Anxiety and panic attacks are the most commonly reported
adverse reactions following the use of cannabis. Inexperience and
use in a foreign environment play a major role (58). Though anxi-
ety and panic attacks are often reported, many users take cannabis
for its fear-inhibiting effects [for a review, see Ref. (59)]. THC
seems to be responsible for the anxiogenic effects of cannabis [e.g.,
Ref. (58, 60, 61)].
By the early 1980s, it had been shown that THC led to a signifi-
cant increase of acute anxiety symptoms, while CBD had no effect
(42). When CBD and THC were administered together, the anxio-
genic effect of THC was halved. This was an important indication
that the anxiety-inducing effects of THC could be antagonized
by CBD. The results from later studies, however, were inconsis-
tent; the anxiety-reducing effect of CBD was not found in all
subsequent studies. Ilan and colleagues investigated the contri-
bution of THC and CBD to the subjective and behavioral effects
of smoked marijuana (62). In their study, 23 healthy marijuana
users were randomly assigned to a low- or a high-THC group and
low or high levels of CBD. In the four sessions under blinded con-
ditions, subjects smoked marijuana cigarettes containing placebo
(no active cannabinoids) or cigarettes containing THC with low or
high levels of CBD. Compared with the placebo, cannabis caused
a slight short-term increase in anxiety symptoms (VAS). These
effects were greatest in the high-THC condition and appeared to
diminish when the CBD content was high, but this latter effect was
Table 1 | Summary of “naturalistic” studies in which the effects of cannabidiol and cannabis with a high dosis ofTHC on psychological
functions have been investigated.
Reference Subjects THC/CBD Results Remarks
Di Forti et al.
(47)
“First-episode”
psychiatric patients
(n=280)
Self reported frequency
and type of cannabis
used
The chance that high-potent cannabis
(THC) has been used is higher among
“first-episode” psychotic patients than
among non-psychotics
Also more frequent use in
“first-episode” psychotic patients
Morgan and
Curran (45)
Cannabis users
(n=154)
Grouping based on
presence of THC and/or
CBD in hair
More psychotic symptoms among THC
group in comparison with no THC group
and in group with THC and CBD in hair
THC might be psychotogenic and
CBD might protect against this
effect
Schubart et al.
(48)
Websurvey among
cannabis users
(n=1877)
Grouping based on self
reported preference for
type of cannabis
Less psychotic symptoms in cannabis
users who use cannabis with high level of
CBD (hash)
Personal communication with
author (Schubart)
Morgan et al.
(46)
Cannabis users, at least
once a month (n=134)
Choosing cannabis by
cannabis user
Acute effects on mood, psychotic
symptoms, and cognition
CBD attenuates the THC-induced
memory impairment; CBD does not
affect psychotomimetic symptoms
Morgan et al.
(49)
Recreational cannabis
users (n=54) versus
daily users (n=66)
Measuring THC and
CBD in hair
THC increases possibility of negative
psychotic symptoms, CBD antagonizes
(part of) THC-induced effects
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Table 2 | Overview of studies investigating the effect of cannabidiol or cannabidiol in combination withTHC on psychological functions in
humans. Studies in which cannabis extracts have been used are not included.
Reference Subjects DosingTHC/CBD Results Comments
Karniol et al. (64) Healthy volunteers
(n=40)
30 mg THC (oral); 15, 30
of 60 mg CBD (oral) or
in combination with
30 mg THC (both oral)
Antagonizing (part of) the
THC-induced effects
CBD decreased the anxiety
component of THC effects; no
effect of CBD alone
Hollister and
Gillespie (65)
Healthy volunteers
(n=30)
20 mg THC+40 mg
CBD (both oral)
CBD delays onset of the effect of
THC and prolongs the effects ofTHC
Dalton et al. (66) Healthy volunteers
(n=15)
25µg/kg BW THC and
150µg/kg BW CBD via
smoking a joint
CBD reduces euphoric effect of THC Only effective when CBD and
THC are administered
simultaneously
Hollister (67) Healthy volunteers
(n= ?)
CBD 5–30 mg i.v. No effects
Carlini and Cunha
(68)
Healthy volunteers Acute 600 mg CBD;
10 mg/kg/BW CBD
20 days
CBD does not have psychological or
physical effects
Light drowsiness after CBD
administration
Zuardi et al. (42) Healthy volunteers
(n=8)
0.5 mg/kg BW
THC+1 mg/kg BW CBD
(both oral)
CBD antagonizes psychological
effects of THC (anxiety)
CBD itself has no effect and
does not antagonize the physical
effects of THC (HR, BP)
Zuardi et al. (69) Treatment resistant
schizophrenic
patients (n=3)
CBD during 29 days
upwards from 40 to
1280 mg/day (oral)
CBD does not antagonize
symptoms
No side effects of CBD reported
Crippa et al. (70) Healthy volunteers
(n=10)
CBD 400 mg oral Anxiolytic effects; light mental
sedation
SPECT results: effects in left
amygdala-hippocampus complex
radiating to hypothalamus
Leweke et al. (71) Psychiatric patients
(n=43)
CBD oral 800 mg/day;
during 4 weeks
CBD more effective as antipychotic
than amsulpride
Less side effects of CBD than
with amsulpride
Zuardi et al. (72) PD patients with
psychoses
CBD 150 mg/day;
during 4 weeks
CBD possibly effective for
treatment of PD patients suffering
from psychoses
No significant side effects of
CBD reported
Borgwardt et al. (73),
Fusar-Poli et al. (74),
Fusar-Poli et al. (75),
Bhattacharyya et al.
(76)a
Healthy volunteers
(n=15)
CBD oral 600 mg;
10 mg THC (not
simultaneously); in
comparison with
placebo
No effect in contrast with THC; CBD
activates other brain areas than THC
no effects of CBD in verbal learning
task and no induction of psychotic
symptoms
No sedation and no inhibition of
locomotion by CBD; THC induces
psychotic symptoms, anxiety,
and sedation
Zuardi et al. (77) Patients with bipolar
disorder (n=2)
CBD oral
600 – 1200 mg/day
during 25 days
CBD has no effect on symptoms No side effects of CBD reported
Bhattacharyya et al.
(43)
Healthy volunteers
(n=6)
CBD 5 mg i.v.
immediately followed
by 1.25 mg THC i.v.
CBD antagonizes THC-induced
psychotic symptoms
CBD and THC have opposite
effects on regional brain function
Bergamaschi et al.
(78)
Healthy controls
(n=12) and patients
with social phobia
(n=24)
CBD oral 600 mg Reduction of anxiety scores in
patients, no effect in controls
No physical effects or side
effects of CBD reported
(Continued)
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Table 2 | Continued
Reference Subjects DosingTHC/CBD Results Comments
Crippa et al. (79) Patients with social
phobia (n=10)
CBD oral 400 mg No effect on psychological scores No physical effects; SPECT: CBD
exerts its effects via limbic and
paralimbic areas
Nicholson et al. (80) Healthy volunteers
(n=8)
CBD 5 mg+THC 5 mg;
CBD 15 mg+THC
15 mg, via mouth spray
THC (15 mg) increases drowsiness,
antagonized by CBD (15 mg)
Hallak et al. (81) Schizophrenic
patients (n=28)
CBD oral 300 and
600 mg acute
No positive effects in Stroop Color
Word Test
No significant side effects of
CBD reported
Hallak et al. (82) Healthy volunteers
(n=10)
CBD oral 600 mg and
ketamine i.v.
CBD increases activating effects of
ketamine (BPRS); reduction of
ketamine-induced depersonalization
(CADSS)
No effect of CBD on HR and BP
aThis concerns experiments with one group of 15 subjects from which the results have been spread over four different publications; BP, blood pressure; BW, body
weight; CADSS, Clinician Administered Dissociative States Scale; HR, heart rate; i.v., intravenously; PD, Parkinson disease.
not statistically significant. Because this increase in anxiety was
generally mild and because not all subjects responded with fear, a
follow-up analysis with only the anxious subjects was performed.
There was a non-significant trend for less anxiety in the high-
versus the low-CBD condition in subjects who reported higher
levels of anxiety after smoking the joints. A reason for the absence
of significant results in this study might be that neither the THC
nor the CBD concentrations were high enough to have signifi-
cant effects. In the studies in which anxiety-reducing effects were
reported, high oral doses of CBD typically were involved. Cannabis
that is used for recreational purposes does not contain such high
amounts of CBD.
People with cannabis dependence are more likely to suffer from
an anxiety disorder and, in particular, from social anxiety disorder
[for a review, see Ref. (58)].
So far, studies investigating the relationship between cannabis
dependence and anxiety disorders have not clarified the nature of
the relationship in question: does cannabis use lead to anxiety dis-
orders or do anxiety disorders lead to the (over-) use of cannabis?
There are no studies in which the relationship between cannabis
use and anxiety disorders is examined and in which an inquiry
about the type of cannabis used or its THC/CBD ratio is included.
In two experiments using patients suffering from social anxiety
disorder along with healthy volunteers as controls, the subjects had
to speak in front of a video camera, regardless of whether they were
under the influence of CBD. In this experimental situation, CBD
was effective in preventing symptoms of anxiety, both in healthy
volunteers and in patients with social anxiety disorder (41, 63).
CBD suppressed the symptoms of anxiety, similar to the action of
the sedatives diazepam and ipsapirone. The main features of the
studies on humans that have investigated the psychological effects
of administering CBD (singularly or in combination with THC)
are summarized in Table 2.
Several studies have shown that cannabis and THC
dose-dependently cause cognitive and psychomotor function
impairments along with memory, (selective) attention, locomotion,
perception, and response impairments (83–85). The effects occur
most strongly during the first hour after smoking a joint and
between 1 and 2 h after oral intake. Little experimental research
exists on the effects of CBD alone or in conjunction with THC on
cognitive and psychomotor functions. The studies performed so
far show few “protective” effects of CBD on cognitive functions.
Morgan and colleagues identified a few such effects on memory
functions, but the research on this aspect of CBD has inconsistent
findings (45, 49).
Although no human studies have specifically investigated the
long-term effects of the combined effect of THC and CBD on cog-
nitive functioning, there are indications that CBD may have some
neuroprotective properties. In some neurodegenerative diseases
that are often associated with declines in cognitive functioning,
such as Alzheimer’s and Parkinson’s diseases, CBD may have some
role in treatment or prevention (86–89).
The ratio of THC to CBD may play a role in the risk of
addiction (90). Morgan and colleagues examined whether there
is a difference in attentional bias between users of cannabis hav-
ing a relatively high CBD/THC ratio versus cannabis having a
low-CBD/THC ratio. Much weaker attentional bias for cannabis-
related stimuli was found for users of cannabis with a high CBD
content than for users of cannabis with a low-CBD content.
Furthermore, the extent to which both groups appreciated the
self-selected drug and the strength of the desire for their drug
(“wanting”) were investigated. High CBD content led to dimin-
ished appreciation and weaker desire for the drug relative to
low-CBD content. The researchers concluded that cannabis with
a high CBD content confers less risk for developing an addiction
than cannabis with a low-CBD content (90). Whether smoking
hashish in practice diminishes addiction risk in comparison with
smoking highly potent marijuana should be further investigated.
CONCLUSION
Cannabis is not a safe drug. Depending on how often some-
one uses, the age of onset, the potency of the cannabis that is
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used and someone’s individual sensitivity, the recreational use
of cannabis may cause permanent psychological disorders. Many
recreational users of cannabis will never be faced with serious or
permanent health deficits. However, for some users, the use of
cannabis may cause undesirable psychological side effects, such
as cognitive impairment, anxiety and paranoia, and an increased
risk of developing chronic psychosis and addiction. Despite all of
the publicity surrounding cannabis, remarkably few studies have
been performed that examined the relationship between a pos-
sibly harmful effect of THC and a possibly protective effect of
CBD. The few studies that exist on the effects of CBD show that
this cannabinoid can counteract some of the negative effects of
THC, although their results have not always been consistent. The
question remains how the findings from laboratory studies, often
employing high doses of CBD and high CBD/THC ratios, can be
extrapolated to the typical practices of the recreational cannabis
user. Few or no adverse effects of CBD have been proffered, and
where CBD has been found to have an effect, it is usually in a“posi-
tive” (i.e., salubrious) direction. The evidence favoring a beneficial
effect of CBD therefore merits further investigation in studies in
which the amounts and ratios of CBD and THC correspond to the
daily practices of recreational cannabis use.
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